A structured, multidisciplinary VUS resolution workflow enabled considerable VUS reclassification, nearly doubling the diagnostic yield and improvements in diagnostic yield and clinical utility.
Abstract
A nationwide nephrologist-led genetic testing program for suspected monogenic glomerular disease and unexplained chronic kidney disease was implemented across four tertiary hospitals in Singapore. Initial testing yielded a genetic diagnosis in 11.5% probands, while 77 (18.4%) harboured variants of uncertain significance (VUS) that could explain their kidney disease (VUS-congruent). We evaluated a structured pipeline for reclassifying VUS-congruent to likely pathogenic or pathogenic (LP/P) to improve diagnostic yield and clinical utility.
Probands with VUS-congruent were reviewed at monthly multidisciplinary genomic board meetings. A stepwise framework incorporated genotype–phenotype correlations (Step 1), then re-appraisal of existing evidence (Step 2) through review of population databases, literature and in-silico prediction. For VUS with high suspicion of pathogenicity (VUS-High), resolution strategies were recommended (Step 3), including familial variant-specific testing, deeper phenotyping, and functional studies. Primary outcome was the proportion of VUS-congruent reclassified to LP/P; secondary outcomes were improvements in diagnostic yield and clinical utility.
Among 418 probands tested over 28 months, 77 (18.4%) had VUS-congruent. Step 2 reclassified 26/77 VUS-congruent to LP/P, with another 22/77 VUS-congruent stratified as VUS-High. Among these 22 recommended for Step 3, completed strategies were functional studies (n=8), segregation analysis (n=1), deeper phenotyping (n=1), phase determination (n=1) and combination strategies (n=6). This enabled VUS-High reclassification to LP/P for 16 additional probands. Overall, 42/77 probands (54.5%) had VUS-congruent reclassified to LP/P, increasing diagnostic yield from 11.5% to 21.5%. Among these, 28 (66.7%) experienced clinically meaningful management changes.
A structured, multidisciplinary VUS resolution workflow enabled considerable VUS reclassification, nearly doubling the diagnostic yield.
Background/Objectives: Interpretation of NOTCH2 variants of uncertain significance (VUSs) remains challenging in pediatric cholestasis and suspected Alagille syndrome (ALGS) due to incomplete penetrance, phenotypic variability, and extensive genetic variation. Although disease-specific variant classification criteria h...
Brett J. Hoskins, T. Pramparo, S. Vandriel et al.· Genes· 0 citations
In this large HCM cohort, variant re-evaluation resulted in a modest but clinically relevant reclassification of genetic variants, consistent with consolidation of locus-specific evidence and important given their association with adverse outcomes, despite modest hypertrophy.
A. Bakalakos, Rebeca Lorca, A. Protonotarios et al.· European Journal of Human Ge...· 0 citations
Malignant Hyperthermia Susceptibility (MHS) is most commonly caused by pathogenic variants in the RYR1 gene. The proliferation of RYR1 Variants of Uncertain Significance (VUS) on diagnostic genetic panels poses a significant clinical challenge, often leading to unnecessarily complex clinical concerns. We report the cas...
Isabella Mullally, Eugene Smith, Péter Bedőcs et al.· Genes· 0 citations
The increasing use of next-generation sequencing (NGS), including multigene panels and exome and genome sequencing, has led to increased identification of rare and previously unreported variants in Mendelian disorders, though evidence supporting their clinical interpretation remains limited. In Fabry disease (FD), this...
F. Pieruzzi, R. Mignani, S. Feriozzi et al.· Journal of Clinical Medicine· 0 citations
In males, MECP2 loss of function was long thought to be lethal or uniformly severe, and affected boys remain under-recognised. Their clinical range is still poorly defined. We assembled a multicentre Turkish series of 22 hemizygous male probands ascertained through routine diagnostic testing rather than severe-phenotyp...
Çağrı Doğan, Mehmet Burak Mutlu, A. Cansu et al.· BMC Pediatrics· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.